Edition:
United Kingdom

Protagonist Therapeutics Inc (PTGX.OQ)

PTGX.OQ on NASDAQ Stock Exchange Global Market

18.99USD
15 Dec 2017
Change (% chg)

$0.76 (+4.17%)
Prev Close
$18.23
Open
$18.29
Day's High
$19.44
Day's Low
$18.29
Volume
184,135
Avg. Vol
37,916
52-wk High
$23.35
52-wk Low
$8.00

Summary

Name Age Since Current Position

Harold Selick

62 Independent Chairman of the Board

Dinesh Patel

59 2008 President, Chief Executive Officer, Director

Thomas O'Neil

51 2016 Chief Financial Officer

William Hodder

52 2014 Senior Vice President - Corporate Development

David Liu

66 2016 Chief Scientific Officer, Head of Research & Development

Ashok Bhandari

52 2016 Vice President - Chemistry

Larry Mattheakis

59 2016 Vice President - Biology

Mark Smythe

51 2013 Vice President -Technology & Alliances

Thamil Annamalai

56 2014 Senior Director - Pre-clinical Development

Richard Shames

56 2015 Chief Medical Officer

Lucio Tozzi

52 2015 Senior Director - Clinical Operations

Chaitan Khosla

51 2014 Independent Director

Julie Papanek

33 2015 Independent Director

Armen Shanafelt

57 2010 Independent Director

William Waddill

59 2016 Independent Director

Lewis Williams

67 2017 Independent Director

Biographies

Name Description

Harold Selick

Dr. Harold E. (Barry) Selick, Ph.D., serves as Independent Chairman of the Board of the Company. Dr. Selick has served on our board of directors since February 2009. Dr. Selick has served as the Chief Executive Officer and a director of Threshold Pharmaceuticals, Inc. since June 2002. From June 2002 until July 2007, Dr. Selick was also a Venture Partner of Sofinnova Ventures, Inc., a venture capital firm. From January 1999 to April 2002, he was Chief Executive Officer of Camitro Corporation, a biotechnology company. From 1992 to 1999, he was at Affymax Research Institute, the drug discovery technology development center for Glaxo Wellcome plc, most recently as Vice President of Research. Prior to working at Affymax he held scientific positions at Protein Design Labs, Inc. and Anergen, Inc. Dr. Selick serves as Lead Director of PDL, a public company, and serves as Chairman of the board of directors of Catalyst Biosciences, a public company. Dr. Selick received his B.A. in Biophysics and Ph.D. in Biology from the University of Pennsylvania and was a Damon Runyon-Walter Winchell Cancer Fund Fellow and an American Cancer Society Senior Fellow at the University of California, San Francisco.

Dinesh Patel

Dr. Dinesh V. Patel, Ph.D., serves as President, Chief Executive Officer, Director of the Company. Dr. Patel has served as a member of our board of directors and as our President and Chief Executive Officer since December 2008. Dr. Patel has more than 30 years of executive, entrepreneurial, and scientific experience spanning the pharmaceutical, biotechnology and biopharmaceutical industries. Prior to joining Protagonist, Dr. Patel served from 2006 to 2008 as the President and Chief Executive Officer of Arête Therapeutics, a privately held company focused on the development of drugs for metabolic syndrome. Prior to that, he was the President and Chief Executive Officer of Miikana Therapeutics, an oncology based company, from 2003 until it was acquired by Entremed (later renamed CASI Pharmaceuticals) in 2005. Prior to Miikana, Dr. Patel held positions of increasing responsibility at Versicor (later renamed Vicuron and which was acquired by Pfizer in 2015), from 1996 to 2003, most recently as Senior Vice President of Drug Discovery and Licensing. Prior to Vicuron, Dr. Patel was a director of chemistry at the combinatorial chemistry company Affymax, from 1993 to 1996. Dr. Patel was a medicinal chemist at Bristol-Myers Squibb from 1985 to 1993. Dr. Patel received his Ph.D. in Chemistry from Rutgers University, New Jersey and his B.S. in Industrial Chemistry from S. P. University, Vallabh Vidyanagar, India.

Thomas O'Neil

Mr. Thomas P. (Tom) O'Neil serves as Chief Financial Officer of the Company. Mr. O’Neil has served as our Chief Financial Officer since February 2016. From March 2015 to October 2015, Mr. O’Neil served as Chief Financial Officer of Arcadia Biosciences, Inc., a biopharmaceutical company. From January 2014 to July 2014, Mr. O’Neil served as Chief Financial Officer of Sorbent Therapeutics, Inc., a biopharmaceutical company. From September 2011 to December 2013, Mr. O’Neil served as a consultant to Sorbent and a variety of health care and technology companies. From December 2009 to August 2011, Mr. O’Neil served as Vice President of Finance & Administration of ChemGenex Pharmaceuticals Ltd., a biopharmaceutical company. From March 2007 to May 2009, Mr. O’Neil served as Vice President of Finance & Administration of Nodality, Inc., a biotechnology company. Mr. O’Neil holds a B.A. from Pomona College in International Relations and an M.B.A. from the University of California at Los Angeles.

William Hodder

Mr. William A. Hodder serves as Senior Vice President - Corporate Development of the Company. Mr. Hodder has served as our Senior Vice President of Corporate Development since 2014. Prior to Protagonist, Mr. Hodder was Vice President, Business Development of Promedior, Inc. a clinical stage biotechnology company developing therapeutics for the treatment of fibrosis, from December 2013 to July 2014. Prior to joining Promedior, Mr. Hodder was a founder and CEO of start-up biotechnology company Trenovus, Inc., from 2010 to 2012. Previously, Mr. Hodder was Vice President of Business Development and Corporate Officer at FibroGen, Inc. Prior to joining FibroGen, he served a Director of Business Development and Marketing at Aradigm, a drug delivery company. Mr. Hodder received an M.B.A. from The University of Chicago Booth School of Business and received a B.S. in biology from Oakland University.

David Liu

Dr. David Y. Liu, Ph.D., serves as Chief Scientific Officer, Head of Research & Development of the Company. Dr. Liu has served as our Chief Scientific Officer (CSO) since May 2013 and has served as CSO and Head of Research and Development since February 2016. Prior to Protagonist, Dr. Liu was the Chief Operating Officer and a co-founder of Trenovus, Inc., from 2010 to 2012. Prior to Trenovus, Dr. Liu was Vice President of Research at FibroGen Inc., from 2002 to 2010. Prior to Fibrogen, Dr. Liu served as Director of Inflammation Research at Scios, Inc., now part of Johnson & Johnson, from 1992 to 2002. Dr. Liu held a position as an academic researcher at Brigham and Women’s Hospital, Harvard Medical School and was Instructor and Assistant Professor in the Department of Medicine, Harvard Medical School, from 1976 to 1986. Dr. Liu received his Ph.D. in microbiology and immunology from Michigan State University, and his B.S. in chemistry from The University of Chicago.

Ashok Bhandari

Dr. Ashok Bhandari, Ph.D., serves as Vice President - Chemistry of the Company. Dr. Bhandari joined Protagonist in 2011 and has served as our Vice President of Chemistry since February 2016. He has over 20 years of experience in the technology industry with expertise in peptide, medicinal, and combinatorial chemistry. Prior to joining Protagonist, Dr. Bhandari served as Associate Director of Chemistry at Affymax from 1994 to 2008. Dr. Bhandari has extensive experience with different peptide drug discovery and pre-clinical development programs on targets of protein-protein interactions. He received his Ph.D. in chemistry from Indian Institute of Chemical Technology, India and conducted post-doctoral research at University of California, Santa Barbara.

Larry Mattheakis

Dr. Larry Mattheakis, Ph.D., serves as Vice President - Biology of the Company. Dr. Mattheakis joined Protagonist in 2012 and has served as our Vice President of Biology since 2016. Prior to joining Protagonist, Dr. Mattheakis served as the Associate Director at Exelixis, a publicly traded biotechnology company, from 2007 to 2011. Prior to Exelixis, he served as Senior Scientist at Cytokinetics from 2002 to 2007. Dr. Mattheakis began his career at Affymax Research Institute, where he served in a variety of roles, from 1992 to 2000, most recently as Research Fellow. Dr. Mattheakis received a Ph.D. in Biochemistry from the University of Wisconsin-Madison and a B.S. in Biochemistry from the University of California, Davis. He trained as a post-doctoral research fellow in the Department of Microbiology and Molecular Genetics at Harvard Medical School.

Mark Smythe

Dr. Mark Smythe, Ph.D., serves as Vice President -Technology & Alliances of the Company. Dr. Smythe is the founder of Protagonist and has served as our Vice President of Technology & Alliances since 2013, having previously served as our Chief Scientific Officer from 2009 to 2010 and our Chief Executive Officer from 2001 to 2009. He has extensive experience in industry-based research management and technology commercialization. Prior to Protagonist, he was Principal Investigator at the Centre for Drug Design and Development, now the Institute for Molecular Bioscience in Brisbane, Australia, from 1994 to 2001. Dr. Smythe earned a Ph.D. in Medicinal Chemistry from Melbourne University and a B.Sc (Hons) in Synthetic Organic Chemistry from James Cook University.

Thamil Annamalai

Ms. Thamil Annamalai serves as Senior Director - Pre-clinical Development of the Company. Ms. Annamalai has served as our Senior Director of Pre-clinical Development since March 2014. Ms. Annamalai has 25 years of research and development experience including more than a decade of drug discovery. From 2001 to 2013, Ms. Annamalai served as Manager, Director, and Senior Director for the In Vivo Evaluations group in Pre-clinical Development at Xenoport and was a member of the development team for its flagship product Horizant®. Ms. Annamalai was previously Manager of Pre-clinical Research at Intrabiotics Pharmaceuticals from 1997 to 2001, a biotechnology company focused on novel antimicrobial peptides. Prior to that, she was a Research Pharmacologist at Microcide pharmaceuticals from 1994 to 1997, Research Scientist at Nycomed Salutar from 1991 to 1994, and Toxicologist at Sola Barnes-Hind from 1989 to 1990. Ms. Annamalai received an M. Phil in Human Physiology from the Institute of Basic Medical Science, an M.Sc. in Zoology from Pachaiyappas College, and B.Sc. in Zoology from Stella Maris College, all institutions affiliated with University of Madras, India.

Richard Shames

Dr. Richard S. Shames, M.D., serves as Chief Medical Officer of the Company. Dr. Shames has served as our Chief Medical Officer since August 2015. He currently also serves as Adjunct Associate Clinical Professor of Pediatrics at Stanford University. Prior to joining Protagonist, he served as Senior Vice President and Chief Medical Officer at Aldea Pharmaceuticals, from 2013 to 2015. Prior to Aldea, Dr. Shames was Distinguished Scientist, Clinical Research and Early Biologics Lead (Immunology) at Merck & Co., Inc., from 2009 to 2013. Prior to joining Merck, Dr. Shames held positions of increasing responsibility at Facet Biotech (formerly PDL BioPharma), from 1999 to 2009, most recently as Therapeutic Head of Immunology and Senior Medical Director. Prior to Facet, Dr. Shames held full time clinical faculty positions in Pediatric Allergy and Clinical Immunology at Stanford University, from 1996 to 1999, and the University of California, San Francisco Schools of Medicine, from 1993 to 1996. Dr. Shames received his M.D. from University of California, Davis School of Medicine and received a B.S. in Biological Sciences from Stanford University.

Lucio Tozzi

Mr. Lucio Tozzi serves as Senior Director - Clinical Operations of the Company. Mr. Tozzi has served as our Senior Director of Clinical Operations since July 2015. Mr. Tozzi has over 24 years of experience in global clinical trials spanning pharmaceuticals and medical devices in the therapeutic areas of infections, surgical morbidities, oncology, respiratory and CNS diseases. He has led clinical operations teams with responsibilities for clinical development, outsourcing, and project management. Prior to joining Protagonist, Mr. Tozzi was Senior Director and Head of Clinical Operations at Astex Pharmaceuticals, an oncology company (part of Otsuka), from August 2014 to July 2015. Prior to joining Astex, Mr. Tozzi was Director Clinical Operations at Baxter Healthcare from April 2005 to January 2014. Mr. Tozzi graduated with a BSc (Hons) in Biology from London University, Royal Holloway College, and holds a post-graduate Diploma (DipM) and Membership (MCIM) in Marketing from the Chartered Institute of Marketing.

Chaitan Khosla

Dr. Chaitan S. Khosla, Ph.D., serves as Independent Director of the Company. Dr. Khosla has served as a member of our board of directors since October 2014. Dr. Khosla was the scientific founder and a member of the Board of Directors of Alvine Pharmaceuticals from 2005 until 2016. Prior to Alvine Pharmaceuticals, Dr. Khosla founded and was a director of Kosan Biosciences, from 1995 until it was acquired by Bristol-Myers Squibb in 2008. Dr. Khosla has been a Professor of Chemical Engineering and Chemistry at Stanford University since 2001 and has been a faculty member since 1992. Since 2013, he has served as the founding Director of Stanford ChEM-H. Dr. Khosla is an elected member of the American Academy of Arts & Sciences and the National Academy of Engineering. He is the recipient of several awards, including the 1999 Alan T. Waterman award by the National Science Foundation, the 1999 Eli Lilly Award in biological chemistry and the 2000 ACS Award in pure chemistry. Dr. Khosla is the author of over 300 publications and is an inventor on numerous patents. Dr. Khosla received a Ph.D. from the California Institute of Technology.

Julie Papanek

Ms. Julie Papanek serves as Independent Director of the Company. Ms. Papanek has served as a member of our board of directors since July 2015. Ms. Papanek has been a principal at Canaan Partners, a venture capital firm, since October 2014. Prior to Canaan, Ms. Papanek served in a variety of roles at Genentech across development and commercial, from March 2006 to June 2011. Ms. Papanek received an M.B.A. from the Stanford Graduate School of Business, an MPhil in BioScience Enterprise from Cambridge University, and a B.S. in Molecular Biophysics and Biochemistry from Yale University.

Armen Shanafelt

Dr. Armen B. Shanafelt, Ph.D., serves as Independent Director of the Company. Dr. Shanafelt has served as a member of our board of directors since January 2010. Since April 2009, Dr. Shanafelt has been a partner of Lilly Ventures, a venture capital firm. Prior to joining Lilly Ventures, Dr. Shanafelt was Chief Science Officer responsible for the generation of the early biotherapeutic pipeline for Eli Lilly and Company, a pharmaceutical research company, spanning the therapeutic areas of oncology, endocrine, and neuroscience. Dr. Shanafelt currently serves as Chairman of the board of directors of Aeglea BioTherapeutics, Inc., a public biotechnology company, and serves as a director of the following privately held biotechnology companies: Aileron Therapeutics, Surface Oncology, Sutro Biopharma, and Symic Bio (Chairman). Dr. Shanafelt received his B.S. in Chemistry and Physics from Pacific Lutheran University, and his Ph.D. in Chemistry from the University of California, Berkeley. He completed his postdoctoral work at DNAX Research Institute, where he studied the structure-function relationships of cytokines and their receptors.

William Waddill

Mr. William D. Waddill serves as Independent Director of the Company. Mr. Waddill has served as a member of our board of directors since July 2016. Since April 2014, Mr. Waddill has served as Senior Vice President, Chief Financial Officer, Treasurer and Secretary of Calithera Biosciences, Inc. From October 2007 to March 2014, Mr. Waddill served as Senior Vice President and Chief Financial Officer at OncoMed Pharmaceuticals, Inc., a biopharmaceutical company. From October 2006 to September 2007, Mr. Waddill served as the Senior Vice President, Chief Financial Officer of Ilypsa, Inc., a biotechnology company that was acquired in 2007 by Amgen, Inc. From February 2000 to September 2006, Mr. Waddill served as a Principal at Square One Finance, a financial consulting business. From December 1996 to February 2000, Mr. Waddill served as Senior Director of Finance and Administration at Exelixis, Inc., a biotechnology company. Mr. Waddill received a B.S. in Accounting from the University of Illinois, Chicago, and a certification as a public accountant, which is currently inactive, after working at PricewaterhouseCoopers LLP and Deloitte LLP.

Lewis Williams

Dr. Lewis T. Williams, M.D. Ph.D., serves as Independent Director of the Company. Since January 2002, Dr. Williams has served as a member of the board of directors of Five Prime Therapeutics, Inc. (“Five Prime”) and since August 2011, Dr. Williams has served as President and Chief Executive Officer of Five Prime. Prior to joining Five Prime, Dr. Williams spent seven years at Chiron Corporation, or Chiron, a biopharmaceutical company, now Novartis Vaccines and Diagnostics, Inc., most recently as its Chief Scientific Officer. He also served on Chiron’s board of directors from 1999 to 2001. Prior to joining Chiron, Dr. Williams was a professor of medicine at the University of California, San Francisco and served as director of the University’s Cardiovascular Research Institution and Daiichi Research Center. Dr. Williams also has served on the faculties of Harvard Medical School and Massachusetts General Hospital and co-founded COR Therapeutics, Inc., a biotechnology company focused on cardiovascular disease. He is a member of the National Academy of Sciences and a fellow of the American Academy of Arts and Sciences. Dr. Williams was previously a member of the board of directors of COR Therapeutics, Inc. and Beckman Coulter, Inc., each of which was a public company during his service as a director. Dr. Williams received a B.S. from Rice University and an M.D. and a Ph.D. from Duke University.